NGF mediates the neuroprotective effect of the β2-adrenoceptor agonist clenbuterol in vitro and in vivo: Evidence from an NGF-antisense study

Neurochemistry International

Volumn 35, Issue 1, 1999, Pages 47-57

  Culmsee, C ^a   Semkova, I ^a   Krieglstein, J ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

receptors; Antisense Oligodeoxynucleotides; Astrocytes; Clenbuterol; Focal cerebral ischemia; Nerve growth factor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLENBUTEROL; MESSENGER RNA; NERVE GROWTH FACTOR; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; HIPPOCAMPUS; NERVE CELL CULTURE; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CELLS, CULTURED; CEREBRAL CORTEX; CLENBUTEROL; KINETICS; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RATS; RATS, INBRED F344; RECEPTORS, ADRENERGIC, BETA-2; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PRECURSORS; RNA, MESSENGER; THIONUCLEOTIDES; TRANSCRIPTION, GENETIC;

EID: 0032971356     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(99)00032-7     Document Type: Article

References (32)

1. Carswell S. The potential for treating neurodegenerative disorders with NGF-inducing compounds. Experimental Neurobiology. 124:1993;36-42.
2. Crooke S.T. Basic principles of antisense therapeutics. Crooke S.T. Antisense Research and Application. 1998;1-50 Springer, Berlin, Heidelberg, New York.
3. Culmsee, C., Stumm, R.K., Sohäter, M.K.H., Weihe, E., Kreiglstein, J., 1999. Clenbuterol indexes growth factor mRNA, activates astrocytes and protects rat brain tissue against ischemic damage. European Journal of Pharmacology (in press).
4. Follesa P., Mocchetti I. Regulation of basic fibroblast growth factor and nerve growth factor mRNA by β-adrenergic receptor activation and adrenal steroids in rat central nervous system. Molecular Pharmacology. 43:1993;132-138.
5. Gao W.-Q., Weil R.J., Dugich-Djordjevic M., Lu B. The therapeutic potentials of neurotrophic factors for diseases of the nervous system. Exp. Opin. Ther. Patents. 7:1997;325-338.
6. Hefti F. Pharmacology of neurotrophic factors. Annual Reviews in Pharmacology and Toxicology. 37:1997;239-267.
7. Hayes V.Y., Isackson P.J., Fabrazzo M., Follesa P., Mocchetti I. Induction of nerve growth factor and basic fibroblast growth factor mRNA following clenbuterol: contrasting anatomical and cellular localization. Experimental Neurology. 132:1995;33-41.
8. Hodges-Savola C., Rogers S.D., Ghilardy J.R., Timm D.R., Mantyh P.W. β-Adrenergic receptors regulate astrogliosis and cell proliferation in the central nervous system in vivo. Glia. 17:1996;52-62.
9. Kim S.K., Wold B.J. Stable reduction of thymidine kinase activity in cells expressing high levels of anti-sense RNA. Cell. 42:1985;129-138.
10. Koh J.I., Choi D.W. Vulnerability of cultured cortical neurons to damage by excitotoxins: differential susceptibility of neurons containing NADPH-diaphorase. Journal of Neuroscience. 8:1988;2153-2163.
11. Korsching S., Thoenen H. Nerve growth factor in sympathetic ganglia and corresponding target organs of the rat: correlation with density of sympathetic innervation. Proceedings of the National Academy of Sciences USA. 80:1983;3513-3516.
12. Krieglstein J., Oberpichler-Schwenk H., Prehn J.H.M. Alternative approaches to the pharmacotherapy of ischemia. Ginsberg M.D., Bogousslavsky J. Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. 1998;733-757 Blackwell Science, Malden.
13. Kulka M., Smith C.C., Aurelian L., Fishelevich R., Meade K., Miller P., Ts'o P.O. Site specificity of the inhibitory effects of oligonucleoside methylphosphonates complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. Proceedings of the National Academy of Sciences USA. 86:1989;6868-6872.
14. Levin A.A., Monteith D.K., Leeds J.M., Nicklin P.L., Geary R.S., Butler M., Templin M.V., Henry S.P. Toxicity of oligonucleotide therapeutic agents. Crooke S.T. Antisense Research and Application. 1998;169-216 Springer, Berlin, Heidelberg, New York.
15. Lewin G.R., Barde Y.A. Physiology of the neurotrophins. Annual Reviews in Neuroscience. 19:1996;289-317.
16. Lindsay R.M. Neuroprotective action of the neurotrophins and CNTF in vivo. Krieglstein J. Pharmacology of Cerebral Ischemia 1996. 1996;465-475 Medpharm Scientific Publishers, Stuttgart.
17. Lu B., Yokoyama M., Dreyfus C.F., Black I.B. NGF-gene expression in actively growing brain glia. Journal of Neuroscience. 11:1991;318-326.
18. 2-Adrenergic receptors are expressed by glia in vivo in the normal and injured central nervous system in the rat, rabbit and human. Journal of Neuroscience. 15:1995;152-164.
19. Mocchetti I. Theoretical basis for pharmacology of nerve growth factor biosynthesis. Annual Reviews in Pharmacology and Toxicology. 32:1991;302-328.
20. Nieto-Sampedro M., Lewis E.R., Cotman C.W., Manthorpe M., Skaper S.D., Barbin G., Longo F.M., Varon S. Brain injury causes a time-dependent increase in neuronotrophic activity at the lesion site. Science. 217:1982;860-861.
21. Rudge R.S. Astrocyte-derived neurotrophic factors. Murphy S. Astrocytes: Pharmacology and function. 1993;267-305 Academic Press, New York.
22. Salm A.K., McCarthy K.D. Expression of β-adrenergic receptors by astrocytes isolated from adult rat cortex. Glia. 2:1989;346-352.
23. Schlingensiepen R., Brysch W., Schlingensiepen K.-H. Antisense-from Technology to Therapy. 1997;Blackwell Science, Berlin, Vienna.
24. Sembrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;456 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
25. Semkova I., Culmsee C., Krieglstein J. Neuroprotection caused by NGF and NGF-inducing drugs. Krieglstein J. Pharmacology of Cerebral Ischemia 1996. 1996;477-493 Medpharm Scientific Publishers, Stuttgart.
26. Semkova I., Schilling M., Henrich-Noack P., Rami A., Krieglstein J. Clenbuterol protects mouse cerebral cortex and rat hippocampus from ischemic damage and attenuates glutamate neurotoxicity in cultured hippocampal neurons by induction of NGF. Brain Research. 717:1996;44-54.
27. Semkova I., Wolz P., Schilling M., Krieglstein J. Selegilin enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. European Journal Pharmacology. 315:1996;19-30.
28. Sutin J., Shao Y. Resting and reactive astrocytes express adrenergic receptors in the adult rat brain. Brain Research Bulletin. 29:1992;277-284.
29. Tamura A., Graham D.J., McCulloch J., Teasdale G.M. Focal cerebral ischemia in the rat: regional cerebral blood flow determined by [14C]-iodoantipyrine autoradiography following middle cerebral artery occlusion. Journal of Cerebral Blood Flow and Metabolism. 1:1981;61-68.
30. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends in Pharmacological Sciences. 15:1994;42-46.
31. Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., Yoo H., Inturrisi C.E., Reis J.D. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischemic infarctions. Nature. 363:1993;260-263.
32. Yuen E.C., Mobley W.C. Therapeutic applications of neurotrophic factors in disorders of motor neurons and peripheral nerves. Molecular Medicine Today. 1:1995;278-286.